TITLE

Treating schizophrenia: Game on

AUTHOR(S)
Check Hayden, Erika
PUB. DATE
March 2012
SOURCE
Nature;3/1/2012, Vol. 483 Issue 7387, p24
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the efforts of professor Michael Merzenich to prove the positive effects of his brain-training video game software to people with schizophrenia. It states that Merzenich seeks the approval of U.S. Food and Drug Administration (FDA) for the software that would give schizophrenics a new treatment option. According to Henry Mahncke, chief executive at Posit Science Corp., the memory of people aging 60 years and above have improved after they used the Merzenich's software.
ACCESSION #
72367123

 

Related Articles

  • Dosing and Switching Strategies for Paliperidone Palmitate Based on Population Pharmacokinetic Modelling and Clinical Trial Data. Samtani, Mahesh N.; Gopal, Srihari; Gassmann-Mayer, Cristiana; Alphs, Larry; Palumbo, Joseph M. // CNS Drugs;2011, Vol. 25 Issue 10, p829 

    Paliperidone palmitate is a second-generation, long-acting injectable (LAI) antipsychotic recently approved by the US FDA and European Medicines Agency for use in patients with schizophrenia. This article reviews the re- commended dosing regimens for initiation and maintenance treatment with...

  • Latuda(r) (lurasidone HCl) Label Updated With Expanded Dosing Range Providing Added Flexibility for Treatment of Patients with Schizophrenia.  // Biomedical Market Newsletter;5/7/2012, Vol. 21, p1 

    The article informs that the U.S. Food & Drug Administration (FDA) has approved an expanded dose range for LATUDA from Sunovion Pharmaceuticals Inc. The drug has been developed for the treatment of adult patients with schizophrenia. The maximum recommended dose of LATUDA has been increased from...

  • FDA Actions.  // Internal Medicine Alert;Nov2009 Pharmacology Watch Supp, p2 

    The article reports that the U.S. Food and Drug Administration has approved the use of asenapine for first-line treatment of schizophrenia and bipolar I disorder in adults.

  • Post-Injection Delirium/Sedation Syndrome in Patients Treated with Olanzapine Pamoate: Mechanism, Incidence, and Management. Luedecke, Daniel; Schöttle, Daniel; Karow, Anne; Lambert, Martin; Naber, Dieter // CNS Drugs;Jan2015, Vol. 29 Issue 1, p41 

    Second-generation antipsychotics (SGAs) are a mainstay in the treatment of patients with schizophrenia. However, continuity in intake of the prescribed medication has been one of the greatest challenges in these patients. One option to improve medication adherence is to prescribe depot or...

  • Games -- just what the doctor ordered. Gupta, Sujata // New Scientist;10/1/2011, Vol. 211 Issue 2832, p16 

    The article discusses a cognitive training computer game developed by the company Brain Plasticity which could be approved by the U.S. Food and Drug Administration (FDA) to treat conditions such as schizophrenia and the implications of FDA approval for medical research.

  • Lilly seeks FDA approval for schizophrenia drug.  // Indianapolis Business Journal;9/25/95, Vol. 16 Issue 27, p52A 

    Reports that Eli Lilly & Co. is seeking approval from the Food and Drug Administration to market olanzapine, a drug used to treat schizophrenia and other psychotic disorders. Symptoms of schizophrenia.

  • FDA Actions. Elliott, William T. // Infectious Disease Alert;Jul2009 Supplement, p2 

    The article reports on the need for two topical testosterone gel products to carry boxed warnings on their labeling following a ruling by the U.S. Food and Drug Administration (FDA) that the gels may cause adverse effects in children who are exposed by contact with adults who are using the...

  • Approvals for Zyprexa.  // Monthly Prescribing Reference;Jan2010, Vol. 26 Issue 1, pA11 

    The article reports on the approval of the drug Zyprexa Relprevv from Lilly as treatment for adults with schizophrenia by the U.S. Food and Drug Administration (FDA).

  • Schizophrenia drug approved but with a name change. Ukens, Carol // Drug Topics;2/19/2001, Vol. 145 Issue 4, p12 

    Reports on the approval of Pfizer's ziprasidone HCl for the treatment of schizophrenia by the United States Food and Drug Administration. Potential heart risks of ziprasidone; Results of the worldwide clinical trials for the drug.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics